A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Cancer vaccine MUC-1 (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Immutep Limited; Prima BioMed
- 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
- 26 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 21 May 2015 Results of overall survival analysis in second remission patients published in a Prima BioMed media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History